TLA in Children With Moderate to Severe Atopic Eczema (TLA4AE)

Inclusion Criteria: * Age 4 to 16 years at time of consent * Persistent moderate to severe eczema despite treatment with topical corticosteroids (TCS) Class II or more and/or topical calcineurin inhibitors (TCI, licenced use only) for at least 3 months. * Eczema Area and Severity Index (EASI) Score ≥12 at screening and randomisation visit and \>10% body surface involved * Sensitisation to house dust mite species, confirmed by specific Immunoglobulin E (ImmunoCAP ≥2) and/or Skin Prick Test (SPT ≥5mm) * Child able to sleep in their own bed and able to use the device for at least 5 out of 7 nights per week * Written, informed consent of parent/legal guardian and patient assent Exclusion Criteria: * very severe atopic dermatitis * use of systemic immunosuppression (such as cyclosporine, methotrexate, azathioprine, oral steroids) or UV therapy or extracorporal photopheresis within four weeks prior to the screening visit * received therapeutic monoclonal antibodies (such as Omalizumab or Dupilumab) within six months prior to the screening visit * Ongoing or planned desensitisation / immunotherapy during the study * Infections requiring systemic antimicrobial treatment within four weeks prior to the screening visit * Introduction of special dietary restriction (for eczema treatment) within three months prior to screening visit * Severe asthma ≥ Step 4 and/or ≥1 course of systemic oral steroids for asthma in the three months prior to screening visit * Significant underlying chronic medical condition (chronic other skin disease, inflammatory bowel disease, immunodeficiencies, other uncontrolled systemic disease, cancer) * Planned time away from home (=unable to use TLA) exceeding 2 days/week; unable to use the device at least 5/7 days in the 2-3 weeks prior to end of intervention period. * Prior research participation is not an exclusion criterion, except if it involved eczema disease modifying agents. * Participating in current research